SCM
BLUE

Shelton Capital Management’s bluebird bio BLUE Stock Holding History

Shelton Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-610
Closed -$363K – 681
2020
Q1 		$363K Hold
610
– – 0.03% 350
2019
Q4 		$693K Buy
610
+386
+172% +$420K 0.04% 277
2019
Q3 		$266K Hold
224
– – 0.02% 583
2019
Q2 		$369K Buy
+224
New +$388K 0.02% 448

Other funds holding BLUE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Shelton Capital Management's BLUE Position: Q2 2020 in Review

Shelton Capital Management sold out of bluebird bio (BLUE) in Q2 2020, closing a stake of 610 shares — an estimated $363K sold.

Shelton Capital Management first reported a position in BLUE in Q2 2019 and held it in 4 quarters. The position peaked at $693K in Q4 2019. 278 funds tracked by Wall St. Rank hold BLUE as of Q2 2020.

  • Shelton Capital Management reported no remaining bluebird bio position as of Q2 2020 after selling out during the quarter.
  • Shelton Capital Management sold 610 bluebird bio shares in Q2 2020, an estimated $363K.
  • Shelton Capital Management first reported a position in bluebird bio in Q2 2019 and held it in 4 quarters.
  • Shelton Capital Management's bluebird bio position peaked at $693K in Q4 2019.
  • 278 funds tracked by Wall St. Rank held bluebird bio as of Q2 2020.

Based on Shelton Capital Management's 13F filing for Q2 2020, filed 12 Aug 2020.